BioMarin expects $283 million charge for Alesta acquisition in third quarter
The pharmaceutical company disclosed preliminary financial impacts from its recent acquisition of Alesta Therapeutics.
Key takeaways
- BioMarin Pharmaceutical Inc. (BMRN) disclosed in an 8-K filing that its third-quarter 2026 results will include approximately $283 million in pre-tax charges for the Alesta Therapeutics acquisition, impacting both GAAP and non-GAAP diluted EPS by about $1.50.
BioMarin Pharmaceutical Inc. said in a regulatory filing on Monday that its third-quarter financial results will include pre-tax charges of approximately $283 million of acquired in-process research and development expense in connection with its acquisition of Alesta Therapeutics B.V.
The acquisition was completed on August 31, 2026. The company said the acquired research and development charge and ongoing operating expenses represent an unfavorable impact of approximately $1.50 to both GAAP diluted earnings per share and non-GAAP diluted earnings per share for the third quarter of 2026.
Because the occurrence, magnitude, and timing of such transactions are inherently uncertain, BioMarin did not forecast acquired research and development charges in its full-year 2026 guidance announced on August 6, 2026. The company expects the acquisition to result in total pre-tax charges of approximately $320 million for the full year 2026, consisting of the acquired research and development charges and ongoing operating expenses, including transaction and transition costs.
These full-year charges represent an unfavorable impact of approximately $1.55 to both GAAP diluted earnings per share and non-GAAP diluted earnings per share. BioMarin expects to provide updated full-year 2026 guidance in connection with its third-quarter 2026 financial results.
The results for the quarter ended September 30, 2026, have not been finalized and are subject to financial statement closing procedures, according to the filing.